Resultados de búsqueda - Xiaojing Lin

  • Mostrando 1 - 2 Resultados de 2
Limitar resultados
  1. 1

    Preclinical and first-in-human of purinostat mesylate, a novel selective HDAC I/IIb inhibitor, in relapsed/refractory multiple myeloma and lymphoma por Linyu Yang, Qiang Qiu, Jie Wang, Yi Wen, He Li, Rui Liang, Yunyu Feng, Fang Wang, Xiaojing Lin, Minghai Tang, Jianhong Yang, Heying Pei, Peng Zhao, Jishi Wang, Jin Xiang, Jia Miao, Li Zheng, Ke Tan, Yongsheng Wang, Yiguo Hu, Lijuan Chen, Weili Zhao, Ting Niu

    Publicado 2025-06-01

    Abstract Simultaneously targeting key pathogenic drivers and remodeling of the tumor microenvironment represents a critical therapeutic strategy for relapsed or refractory (r/r) multiple myeloma (MM) and lymphoma. Purinostat mesylate (PM), a highly selective HDAC I/II binhibitor, exhibits excellent...

    Descripción completa

    Enlace del recurso
    Artículo
  2. 2